RxDoctor Payments Data

Lucille Venturanza, MD

Psychiatry · Towanda, PANPI 1033269881

Payments from drug & device makers

$5,501in general payments, 2019–2025

Across 201 payments — averaging $27.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$860
  • Alkermes, Inc.$766
  • Otsuka America Pharmaceutical, Inc.$736
  • Vanda Pharmaceuticals Inc.$623
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$601
  • E.r. Squibb & Sons, L.L.C.$579
  • plus $1K from 5 others

What the payments were for

  • Food & beverage$5,501100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,501 in reported general payments places this provider in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,970
Medicare patients
138
Services billed
834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate25$203,317
RexultiBrexpiprazole45$73,896
Invega SustennaPaliperidone Palmitate18$48,377
ZyprexaOlanzapine25$31,703
TrintellixVortioxetine Hydrobromide40$19,385
Aripiprazole224$12,878
Lurasidone Hcl76$10,802
Quetiapine Fumarate346$7,831
Olanzapine253$7,789
Clozapine94$7,402
Bupropion XlBupropion Hcl241$4,190
Divalproex Sodium ErDivalproex Sodium145$3,737
Doxepin Hcl211$3,112
Duloxetine Hcl180$2,800
Risperidone207$2,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$860$203,31725 claims
Otsuka America Pharmaceutical, Inc.Rexulti$736$73,89645 claims
Johnson & JohnsonInvega Sustenna$334$48,37718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Towanda

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →